XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Pectasides, Dimitrios ^a   Papaxoinis, George ^a   Kalogeras, Konstantine T ^b,c   Eleftheraki, Anastasia G ^c   Xanthakis, Ioannis ^b   Makatsoris, Thomas ^d   Samantas, Epaminondas ^e   Varthalitis, Ioannis ^f   Papakostas, Pavlos ^g   Nikitas, Nikitas ^a   Papandreou, Christos N ^h   Pentheroudakis, George ⁱ   Timotheadou, Eleni ^b   Koutras, Angelos ^d   Sgouros, Joseph ^e   Bafaloukos, Dimitrios ^j   Klouvas, George ^j   Economopoulos, Theofanis ^k   Syrigos, Konstantinos N ^l   Fountzilas, George ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Hellenic Cooperative Oncology Group   (Greece)

^d UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^e AGII ANARGIRI CANCER HOSPITAL   (Greece)

^f General Hospital of Chania   (Greece)

^g HIPPOKRATION HOSPITAL   (Greece)

^h UNIVERSITY HOSPITAL OF LARISSA   (Greece)

ⁱ UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^j METROPOLITAN HOSPITAL   (Greece)

^k NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^l SOTIRIA GENERAL HOSPITAL   (Greece)

more..

Author keywords

Angiogenic markers; Bevacizumab; Capecitabine; Chemotherapy; Colorectal cancer; Irinotecan

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; NITRIC OXIDE; OSTEOPONTIN; PYRIDOXINE; RECOMBINANT ERYTHROPOIETIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN A;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CHOLINERGIC SYNDROME; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DYSPHONIA; ELECTROLYTE DISTURBANCE; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEART DISEASE; HICCUP; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INFECTION; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENIC PROTEINS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OSTEOPONTIN; TREATMENT OUTCOME;

EID: 84862991983     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-271     Document Type: Article

References (27)

1. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008, 26:689-690. 10.1200/JCO.2007.15.5390, 18235136.
2. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25:4779-4786. 10.1200/JCO.2007.11.3357, 17947725.
3. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011, 60:116-129. 10.1136/gut.2009.206250, 3006043, 20921207.
4. Köhne CH, De Greve J, Hartmann JT Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Müller L, Janssens J, Bokemeyer C, Reimer P, Link H, Späth-Schwalbe E, Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008, 19:920-926. 10.1093/annonc/mdm544, 18065406.
5. García-Alfonso P, Muñoz-Martin AJ, Alvarez-Suarez S, Jerez-Gilarranz Y, Riesco-Martinez M, Khosravi P, Martin M. Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. Br J Cancer 2010, 103:1524-1528. 10.1038/sj.bjc.6605907, 2990572, 20978503.
6. Ardavanis A, Kountourakis P, Mantzaris I, Malliou S, Doufexis D, Sykoutri D, Fragos I, Rigatos G. Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen. Anticancer Res 2008, 28:3087-3092.
7. Degirmenci M, Karaca B, Gorumlu G, Durusoy R, Demir Piskin G, Bozkurt MT, Cirak Y, Tunali D, Karabulut B, Sanli UA, Uslu R. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Med Oncol 2010, 27:585-591. 10.1007/s12032-009-9253-5, 19526201.
8. Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, Godderz W, Majer K, Flieger D, Teufel A, Siebler J, Hoehler T, Galle PR, Kanzler S. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 2009, 15:449-456. 10.3748/wjg.15.449, 2653366, 19152449.
9. Ducreux M, Adenis A, Mendiboure J, François E, Boucher E, Chauffert B, Ychou M, Pierga J, Montoto-Grillot C, Conroy T. Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study) [abstract]. J Clin Oncol 2009, 27(15s):4086.
10. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007, 370:135-142. 10.1016/S0140-6736(07)61086-1, 17630036.
11. Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, Rossi C, Baldelli AM, Graziano F, Saba V, Muretto P, Catalano G. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000, 6:2803-2807.
12. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000, 36:748-753. 10.1016/S0959-8049(00)00003-4, 10762747.
13. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, Pignatelli C, Galizia G. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 2004, 100:270-278. 10.1002/cncr.11911, 14716760.
14. Hong S, Lee HJ, Kim SJ, Hahm KB. Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-beta signaling. World J Gastroenterol 2010, 16:2080-2093. 10.3748/wjg.v16.i17.2080, 2864833, 20440848.
15. Robson H, Anderson E, James RD, Schofield PF. Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 1996, 74:753-758. 10.1038/bjc.1996.432, 2074698, 8795578.
16. Shim KS, Kim KH, Han WS, Park EB. Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer 1999, 85:554-561. 10.1002/(SICI)1097-0142(19990201)85:3<554::AID-CNCR6>3.0.CO;2-X, 10091729.
17. Tsushima H, Ito N, Tamura S, Matsuda Y, Inada M, Yabuuchi I, Imai Y, Nagashima R, Misawa H, Takeda H, Matsuzawa Y, Kawata S. Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res 2001, 7:1258-1262.
18. Hazar B, Polat G, Bagdatoglu O, Seyrek E, Tezcan Y, Kanik A. The role of fibronectin and nitric oxide (NO) in gastrointestinal cancers. Hepatogastroenterology 2005, 52:119-122.
19. Akbulut H, Altuntas F, Akbulut KG, Ozturk G, Cindoruk M, Unal E, Icli F. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine 2002, 20:184-190. 10.1006/cyto.2002.1993, 12543084.
20. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010, 28:453-459. 10.1200/JCO.2009.24.8252, 2815707, 20008624.
21. Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 2008, 8:212-226. 10.1038/nrc2345, 2484121, 18292776.
22. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002, 94:513-521. 10.1093/jnci/94.7.513, 11929952.
23. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004, 10:184-190. 10.1158/1078-0432.CCR-1405-2, 14734468.
24. Rohde F, Rimkus C, Friederichs J, Rosenberg R, Marthen C, Doll D, Holzmann B, Siewert JR, Janssen KP. Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer 2007, 121:1717-1723. 10.1002/ijc.22868, 17565744.
25. Carrer A, Zacchigna S, Balani A, Pistan V, Adami A, Porcelli F, Scaramucci M, Roseano M, Turoldo A, Prati MC, Dell'Omodarme M, de Manzini N, Giacca M. Expression profiling of angiogenic genes for the characterization of colorectal carcinoma. Eur J Cancer 2008, 44:1761-1769. 10.1016/j.ejca.2008.05.014, 18656346.
26. Likui W, Hong W, Shuwen Z. Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg 2010, 14:74-81. 10.1007/s11605-009-1035-z, 19763701.
27. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001, 7:4060-4066.